Wellington Management Group
OVID icon

Wellington Management Group’s Ovid Therapeutics OVID Stock Holding History

Wellington Management Group’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$278K Buy
+103,400
New +$267K ﹤0.01% 1870
2024
Q3 		– Sell
-115,832
Closed -$89.1K – 1997
2024
Q2 		$89.1K Sell
115,832
-107,061
-48% -$298K ﹤0.01% 1871
2024
Q1 		$680K Buy
+222,893
New +$746K ﹤0.01% 1767

Other funds holding OVID

JT
Jupiter Topco New York $245B AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Wellington Management Group's OVID Position: Q2 2026 in Review

Wellington Management Group opened a new position in Ovid Therapeutics (OVID) in Q2 2026: 103,400 shares worth $278K. The stake represents ﹤0.01% of the portfolio and ranks #1870 among its holdings. This is a return to the name: Wellington Management Group previously reported a position in OVID as recently as Q2 2024.

Wellington Management Group first reported a position in OVID in Q1 2024 and has held it in 3 quarters since. The position peaked at $680K in Q1 2024. 130 funds tracked by Wall St. Rank hold OVID as of Q2 2026.

  • Wellington Management Group held 103,400 shares of Ovid Therapeutics worth $278K as of Q2 2026.
  • Ovid Therapeutics was a new Wellington Management Group position in Q2 2026.
  • Ovid Therapeutics made up ﹤0.01% of Wellington Management Group's portfolio in Q2 2026, its #1870 holding.
  • Wellington Management Group first reported a position in Ovid Therapeutics in Q1 2024 and has held it in 3 quarters since.
  • Wellington Management Group's Ovid Therapeutics position peaked at $680K in Q1 2024.
  • 130 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2026.

Based on Wellington Management Group's 13F filing for Q2 2026, filed 14 Aug 2026.